Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DoximityDOCS -3.46%82 3-Year EPS without NRI Growth Rate is 27.70% as of Mar. 2026, which is 49% below its 10-year median of 54.20. GuruFocus rates DOCS with a GF Score™ of 82/100 and a GF Value™ of $49.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 510 Healthcare Providers & Services companies, Doximity ranks better than 70% on this metric.
During the past 12 months, Doximity's average EPS without NRI Growth Rate was 7.00% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 27.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 36.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Doximity was 549.00% per year. The lowest was 20.10% per year. And the median was 54.20% per year.
Doximity (NYSE:DOCS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Doximity 3-Year EPS without NRI Growth Rate Related Terms
DOCS vs WAY, PRVA, HTFL: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Doximity's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doximity 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Doximity's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Doximity's 3-Year EPS without NRI Growth Rate falls into.
Doximity 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 27.70% mean?
Doximity (DOCS) has a 3-Year EPS without NRI Growth Rate of 27.70% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Doximity and its competitors. This is 49% below median its historical median of 54.20. Over the past decade, Doximity's 3-Year EPS without NRI Growth Rate has ranged from 20.10 to 549.00. According to the industry distribution chart, Doximity ranks #153 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 30%.
Is Doximity's 3-Year EPS without NRI Growth Rate too high?
Doximity's current 3-Year EPS without NRI Growth Rate of 27.70% is 49% below median its 10-year median of 54.20. Over the past 10 years, this metric has ranged from a low of 20.10 to a high of 549.00. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.65. Doximity's value of 27.70% is 137.8% above this industry median. Based on the distribution chart, Doximity ranks #153 out of 510 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Doximity has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's 3-Year EPS without NRI Growth Rate compare to WAY and PRVA?
According to the Healthcare Providers & Services industry distribution chart, Doximity ranks #153 out of 510 companies for 3-Year EPS without NRI Growth Rate. This puts Doximity in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.65. Doximity's value of 27.70% is 137.8% above this benchmark. Historically, Doximity's own 3-Year EPS without NRI Growth Rate has ranged from 20.10 to 549.00 over the past decade. While the company's 10-year median is 54.20 vs. the industry median of 11.65, Doximity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.65, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doximity's current 3-Year EPS without NRI Growth Rate of 27.70% is 137.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Doximity and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doximity's current 3-Year EPS without NRI Growth Rate is 27.70%, which is 49% below median its own 10-year median of 54.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (DOCS) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.35, compared to a current price of $20.38 — trading 58.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 27.70%, which is 49% below median its 10-year median of 54.20 and 137.8% above the Healthcare Providers & Services industry median of 11.65. Doximity's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Doximity (DOCS), the current 3-Year EPS without NRI Growth Rate is 27.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doximity (DOCS) Overvalued in 2026?
Based on GuruFocus' analysis, Doximity stock appears to be undervalued.
The current stock price of $20.38 is trading 58.7% below its estimated GF Value™ of $49.35.
GuruFocus considers Doximity to be Significantly Undervalued.
Key valuation signals for DOCS:
3-Year EPS without NRI Growth Rate: 27.70% (49% below median its 10-year median of 54.20)
GF Value™: $49.35 vs. price of $20.38 (58.7% below fair value)
Industry Position: 137.8% above the Healthcare Providers & Services median (#153 of 510)
No single metric tells the full story. See the DOCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
82GF Score
Get the complete analysis for DOCS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOCS has been successfully added to your 
